LUND, Sweden, Oct. 27, 2020 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) today announced
additional positive interim safety data from its ongoing clinical
Phase I study of the drug candidate ATOR-1017, its wholly owned
4-1BB antibody in development for the treatment of metastasized
cancer.
The Data Review Committee that monitors the safety of the
patients in the Phase I study, has cleared a 100 mg dose and
approved to start dosing at 200 mg, corresponding to approximately
3.2 mg/kg. The majority of the observed drug related adverse events
have been mild or moderate (grade 1 or 2) and there are indications
that ATOR-1017 activates the immune system of patients.
"ATOR-1017 is now administered at the dose levels we aimed for
when designing the study: we are in fact more than 20 times higher
in dose than the benchmark product urelumab. This is an important
milestone for the program and for the upcoming Phase II efficacy
study. ATOR-1017 was designed to overcome the challenges of the
first generation 4-1BB antibodies, in particular severe
immune-related adverse events. The emerging safety profile, based
on data seen this far, suggests that we have been successful",
said Per Norlén, CEO at Alligator Bioscience.
The Phase I study is planned to read out in H1 2021, with a
Phase Ib/II efficacy study starting in H2 2021.
For further information, please contact:
Cecilia Hofvander, Director Investor
Relations & Communications
Phone +46-46-540-82-06
E-mail: cecilia.hofvander@alligatorbioscience.com
This information is such information as Alligator Bioscience
AB (publ) is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through
the agency of the contact person set out above, at 2:00
p.m. CET on October 27,
2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company
developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes the two key assets ATOR-1017 and
mitazalimab. Furthermore, there are two partnered assets;
ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and
AC101 in clinical development by Shanghai Henlius Biotech Inc.). In
addition, the company has developed a novel concept for more
patient-specific immuno-therapy: Neo-X-Prime. Alligator's shares
are listed on Nasdaq Stockholm (ATORX). The Company is
headquartered in Lund, Sweden. For
more information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/predicted-therapeutic-range-dose-levels-reached-in-ator-1017-phase-i,c3226258
The following files are available for download:
https://mb.cision.com/Main/12681/3226258/1326596.pdf
|
Predicted therapeutic
range dose levels reached in ATOR-1017 Phase I
|